
CLAIMS

1. A side chain-linkaged conjugate compound of the Formula (I):



(I)

wherein

"——" represents a single bond; n is 1 to 30;


T is a cell-binding agent/ molecule, selected from the group consisting of an antibody or an antibody fragment that binds to a target cell;

L_1 and L_2 are, the same or different, and when Q_1 or Q_2 is absent L_1 and L_2 are independently selected from O, NH, S, P, NHNH, $N(R_3)$, $N(R_3)N(R_{3'})$, CO, C(O)NH, C(O)O, NHC(O)NH, NHC(O)O, or $N[(CH_2CH_2O)_pR_3]$-$[(CH_2CH_2O)_p{\cdot}R_{3'}]$ and when Q_1 or Q_2 is present, L_1 and L_2 are independently selected from P, N, NNH, or CH, wherein p is independently an integer selected from 0 to about 1000, or combination thereof;

W is a stretcher unit having C_1-C_{18}, normally a self-immolative spacer, a peptidic unit, a hydrazone, a disulfide, a thioether, an ester, or an amide bond; w is 1 or 2 or 3;

V_1 and V_2 are independently a spacer unit and selected from O, NH, S, C_1-C_8 alkyl, C_2-C_8 heteroalkyl, alkenyl, or alkynyl, C_6 aryl, heterocyclic, carbocyclic, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroaralkyl, heteroalkylcycloalkyl, or alkylcarbonyl, or $(Aa)_r$, r =1-12(one to 12 amino acid units), which is composed from a natural or unnatural amino acid, or the same or different sequences of dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit; or $(CH_2CH_2O)_p$, p is 0-1000; and v_1 and v_2 are independently 0, 1 or 2, but v_1 and v_2 are not 0 at the same time; when v_1 or v_2 is 0, it means one of the side chain Q_1 or Q_2 fragment is absent;

Q_1 and Q_2 are independently represented by Formula (I-q1):



(I-q1);


wherein ~~~ is the site linked to L_1 or L_2; G_1 and G_2 are independently selected from NHC(O) or CH_2, ; G_3 is OH, OR_1 or C(O)OH; X_1 is O or CH_2 and X_2 is O, wherein X_1 is O when p_1 is not 0 and at least one of the p_2 and p_3 is 0, and at least one of G_1 and G_2 is NHC(O) when p_3 is 0;

Y_2 is NH; p_1, p_2 and p_3 are independently 0 -100 but are not 0 at the same time; q_1 and q_2 are independently 0 -24;

R_1, R_2, R_3 and $R_{3'}$ are independently H, C_1~C_8 alkyl; C_2~C_8 heteroalkyl, or heterocyclic; C_6 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocyclic, or alkylcarbonyl;

alternatively, any one or more of W, Q_1, Q_2, L_1, L_2, V_1, or V_2, can be independently absent but Q_1, and Q_2 are not absent at the same time;

D is tubulysin analog having the following formula (II):



(II)

or a pharmaceutically acceptable salt, hydrates, or hydrated salt; or a polymorphic crystalline structure; or an optical isomer, racemate, diastereomer or enantiomer thereof,

wherein ----- is a linkage site that links to W independently;

wherein R^1, R^2, R^3, and R^4 are independently H, C_1~C_8 alkyl; C_2~C_8 heteroalkyl, or heterocyclic; C_6 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocyclic, or alkylcarbonyl; or R^1R^2, R^1R^3, R^2R^3, R^3R^4, R^5R^6, $R^{11}R^{12}$ or $R^{13}R^{14}$ form a 3~7 membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic or heteroaromatic ring system; R^1 and R^2 can be independently absent when they link to W independently or simultaneously, Y^1 is N or CH;

wherein R^5, R^6, R^8, R^{10} and R^{11} are independently H, or C_1~C_4 alkyl or heteroalkyl;

wherein R^7 is independently H, R^{14}, $-R^{14}C(=O)X^1R^{15}$; or $-R^{14}X^1R^{15}$; X^1 is O, S, S-S, NH, CH_2 or NR^{14};

wherein R^9 is selected from H, OH, -O-, =O, $-OR^{14}$, $-OC(=O)R^{14}$, $-OC(=O)NHR^{14}$-, $-OC(=O)R^{14}SSR^{15}$-, $OP(=O)(OR^{14})$-, $-OC(=O)NR^{14}R^{15}$, $OP(=O)(OR^{14})$, or $OR^{14}OP(=O)(OR^{15})$ wherein R^{14} is monovalent when coupled to only one other atom and divalent when coupled to two other atoms;

wherein R^{11} is independently H, R^{14}, $-R^{14}C(=O)R^{16}$, $-R^{14}X^2R^{16}$, $-R^{14}C(=O)X^2$, wherein X^2 is -O-, -S-, -NH-, $-N(R^{14})$-, $-O-R^{14}$-, $-S-R^{14}$-, $-S(=O)-R^{14}$-, or $-NHR^{14}$;


wherein R^{12} is R^{15},-OH, -SH,$-NH_2$, NH, $NHNH_2$, $-NH(R^{15})$, $-OR^{15}$, $-R^{15}COR^{16}$, $-R^{15}COOR^{16}$, $-R^{15}C(O)NH_2$, $-R^{15}C(O)NHR^{17}$, $-SR^{16}$, $R^{15}S(=O)R^{16}$, $-R^{15}P(=O)(OR^{17})_2$, $-R^{15}OP(=O)(OR^{17})_2$, $-CH_2OP(=O)(OR^{17})_2$, $-R^{15}SO_2R^{17}$, $-R^{15}X^2R^{16}$, $-R^{15}C(=O)X^2$, where X^2 is -O-, OH, SH, -S-, NH_2, -NH-, $-N(R^{15})$-, $-O-R^{15}$-, $-S-R^{15}$-, $-S(=O)-R^{15}$-, CH_2 or$-NHR^{15}$- wherein R^{15} is monovalent when present alone and divalent when not present alone;

R^{13} and R^{14} are independently H, O, S, NH, $N(R^{15})$, NHNH, -OH, -SH, $-NH_2$, NH, $NHNH_2$, $-NH(R^{15})$, $-OR^{15}$, CO, $-COX^2$, $-COX^2R^{16}$, R^{17}, F, Cl, Br, I, SR^{16}, $NR^{16}R^{17}$, $N{=}NR^{16}$, $N{=}R^{16}$, NO_2, $SOR^{16}R^{17}$, SO_2R^{16}, SO_3R^{16}, OSO_3R^{16}, $PR^{16}R^{17}$, $POR^{16}R^{17}$, $PO_2R^{16}R^{17}$, $OP(O)(OR^{17})_2$, $OCH_2OP(O)(OR^{17})_2$, $OC(O)R^{17}$, $OC(O)OP(O)(OR^{17})_2$, $PO(OR^{16})(OR^{17})$, $OP(O)(OR^{17})OP(O)(OR^{17})_2$, $OC(O)NHR^{17}$; -O-(C_4-C_{12} glycoside), -N-(C_4-C_{12} glycoside); C_1~C_8 alkyl, heteroalkyl; C_2-C_8 of alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; C_6 of aryl, Ar-alkyl, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, or 2- 8 carbon atoms of esters, ether, or amide; or peptides containing 1-8 amino acids $(NH(Aa)_{1\sim8}$ or $CO(Aa)_{1\sim8}$ (N-terminal or C-terminal 1 - 8 the same or different amino acids), or polyethyleneoxy unit of formula $(OCH_2CH_2)_p$ or $(OCH_2CH(CH_3))_p$, wherein p is an integer from 0 to about 1000, or combination of above groups thereof; X^2 is O, S, S-S, NH, CH_2, OH, SH, NH_2, CHR^{14} or NR^{14};

R^{15}, R^{16} and R^{17} is independently H, C_1~C_8 alkyl, heteroalkyl; C_2-C_8 of alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; C_6 of aryl, Ar-alkyl, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, alkylcarbonyl, or Na^+, K^+, Cs^+, Li^+, Ca^{2+}, Mg^+, Zn^{2+}, $N^+(R^1)(R^2)(R^3)(R^4)$, $HN^+(C_2H_5OH)_3$ salt;

Y^1 and Y^2 are independently N or CH; when Y^3 does not exist, Y^4, Y^5, Y^6 and Y^7 are independently CH, N, NH, O, S, or N (R1), thus Y^2, Y^4, Y^5, Y^6 and Y^7form a heteroaromatic ring of furan, pyrrole thiophene, thiazole, oxazole and imidazole, pyrazole, triazole, tetrazole, thiadiazole; when Y^3, Y^4, Y^5, Y^6 and Y^7 are independently CH or N, thus Y^2, Y^3, Y^4, Y^5, Y^6 and Y^7 form aromatic ring of benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine, pentazine.


2. A side chain-linkaged conjugate compound of the Formula (III):



(III)




wherein D, W, w, L_1, L_2, Q_1, Q_2, V_1, V_2, v_1, v_2, n, T are defined the same as in Claim **1**.



3. A side chain-linkage compound of Formula (IV), which can readily react to a cell-binding molecule T to form a conjugate of Formula (I):









(IV)



wherein D, W, w, L_1, L_2, Q_1, Q_2, V_1, V_2, v_1, v_2, and n, are defined the same as in Claim **1**; cell-binding molecule selected from the group consisting of an antibody or an antibody fragment that binds to a target cell; Lv_1 is a reacting group that can be reacted with a thiol, amine, carboxylic acid, selenol, phenol or hydroxyl group on a cell-binding molecule and Lv_1 is selected from OH; F; Cl; Br; I; nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; mono-fluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3′-sulfonate, anhydrides formed its self, or formed with the other anhydride, e.g. acetyl anhydride, formyl anhydride; an anhydride, formed by acid themselves or formed with other C_1~C_8 acid anhydrides; Lv_1 is preferably selected from:




disulfide;

haloacetyl;

acyl halide (acid halide);



N-hydroxysuccinimide ester;




monosubstituted maleimide;

disubstituted maleimide;



monosubstituted succinimide;

disubstituted succinimide;

substituted maleic acid; -CHO aldehyde;

ethenesulfonyl;

acryl (acryloyl);




2-(tosyloxy)acetyl;

2-(mesyloxy)acetyl;





2-(nitrophenoxy)acetyl;

2-(dinitrophenoxy)acetyl;


2-(fluorophenoxy)-acetyl;

 2-(difluorophenoxy)-acetyl;  2-(((trifluorome-


thyl)-sulfonyl)oxy)acetyl,  2-(pentafluorophenoxy)acetyl;

 , methylsulfonephenyloxadiazole (ODA);  , ,

 alkyloxyamino;  azido,  alkynyl, or  hydrazide;


wherein X_1' is F, Cl, Br, I or Lv_3; X_2' is O, NH, N(R_1), or CH_2; R_3 is independently H, aromatic, heteroaromatic, or aromatic group wherein one or several H atoms are replaced independently by -R_1, -halogen, -OR_1, -SR_1, - NO_2, -S(O)R_1,-S(O)$_2R_1$, or -$COOR_1$; Lv_3 is a leaving group selected from F, Cl, Br, I, nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; or 2-ethyl-5-phenylisoxazolium-3′-sulfonate.


4. A side chain-linkage compound of Formula (V), which can readily react to a cell-binding molecule T to form a conjugate of Formula (III):


 (V)


wherein D, W, w, L_1, L_2, Q_1, Q_2, V_1, V_2, v_1, v_2, and n, are defined the same as in Formula (I); wherein Lv_1 and Lv_2 have independently the same definition of Lv_1 in Formula (IV) of Claim **3** and both Lv_1 and Lv_2 can be the same or different in Formula (V); wherein cell-binding molecule is defined the same as in Claim **3**.


5. The compound according to Claim **1 2, 3** or **4** wherein D is selected from I-01 to I-75:


 I-01,



I-02，



I-03，



I-04，



I-05，



I-06，



I-07，



I-08，



I-09，



I-10,



I-11,



I-12,



I-13,



I-14,



I-15,



I-16,



I-17,



I-18,



I-19,



I-20,



I-21,



I-22,



I-23,



I-24,



I-25,



I-26,



I-27,



I-28,



I-29,



I-30,



I-31,



I-32,



I-33,



I-34,



I-35,



I-36,



I-37,



I-38,



I-39,



I-40,



I-41,



I-42,



I-43,



I-44,



I-45,



I-46,



I-47,



I-48,



I-49,



I-50,



I-51,



I-52,



I-53,



I-54,



I-55,



I-56,



I-57,



I-58,



I-59,



I-60,



I-61,



I-62,



I-63,



I-64,



I-65,



I-66,



I-67,



I-68,



I-69,



I-70,


I-71,


I-72,



I-73,


I-74,



I-75,


or their pharmaceutically acceptable salts, hydrates, or hydrated salts; or the polymorphic crystalline structures of these compounds; or their optical isomers, racemates, diastereomers or enantiomers; wherein R^{20} is H; C_1-C_8 of linear or branched alkyl or heteroalkyl; C_2-C_8 of linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 linear or branched of ~~aryl,~~ Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR^{17}), carbamate (-C(O)$NR^{17}R^{18}$); or 1-8 carbon atoms of carboxylate, esters, ether, or amide; or 1~8 amino acids; or polyethyleneoxy unit of formula $(OCH_2CH_2)_p$ or $(OCH_2CH(CH_3))_p$, wherein p is an integer from 0 to about 1000; or R^{20} is absent and the oxygen forms a ketone, or combination above thereof; Z^2 and Z^3 are independently H, OH, NH_2, O, NH, COOH, COO, C(O),C(O), C(O)NH, $C(O)NH_2$, R^{18}, $OCH_2OP(O)(OR^{18})_2$, $OC(O)OP(O)(OR^{18})_2$, $OPO(OR^{18})_2$, $NHPO(OR^{18})_2$, $OP(O)(OR^{18})OP(O)(OR^{18})_2$, $OC(O)R^{18}$, $OC(O)NHR^{18}$, $OSO_2(OR^{18})$, O-(C_4-C_{12}-glycoside), of linear or branched alkyl or heteroalkyl; C_2-C_8 of linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 linear or branched of ~~aryl,~~ Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR^{17}), carbamate (-C(O)$NR^{17}R^{18}$); $R^{17}$and R^{18} are independently H, C_1-C_8 linear or branched alkyl or heteroalkyl; C_2-C_8 of linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 linear or branched of aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate, carbamate; R^7 is independently H, R^{14}, -$R^{14}C(=O)X^1R^{15}$; or -$R^{14}X^1R^{15}$; X^1 is O, S, S-S, NH, CH_2 or NR^{14}. R^7 and R^{14} are defined the same as in claim 1.

6. The compound according to Claim **1, 2, 3,** or **4** wherein W, L_1, L_2, V_1, and V_2 may independently be composed of one or more linker components of the following structures:




6-maleimidocaproyl (MC),







maleimido propanoyl (MP), valine-citrulline (val-cit),




alanine-phenylalanine (ala-phe),




lysine-phenylalanine (lys-phe),




p-aminobenzyloxycarbonyl (PAB),




4-thio-pentanoate (SPP),




4-thio-butyrate (SPDB),




4-(N-maleimidomethyl)cyclo-hexane-1-carboxylate (MCC),




maleimidoethyl (ME),




4-thio-2-hydroxysulfonyl-butyrate (2-Sulfo-SPDB),




aryl-thiol (PySS),




(4-acetyl)aminobenzoate (SIAB),




, oxylbenzylthio,




aminobenzylthio,




dioxylbenzylthio,




diaminobenzylthio,










amino-oxylbenzylthio,







alkoxy amino (AOA),



 ethyleneoxy (EO),  4-methyl-4-dithio-pentanoic (MPDP),



 triazole,  dithio,  alkylsulfonyl,  alkyl-


sulfonamide,  sulfon-bisamide,  Phosphondiamide, 


alkylphosphonamide,  phosphinic acid,  N-methylphosphonamidic





acid,  N,N'-dimethylphosphon-amidic acid,  N,N'-dime-





thylphosphondiamide,  hydrazine,  acetimidamide;




 oxime,  acetylacetohydrazide,  ami-


noethyl-amine,  aminoethyl-aminoethyl-amine, or L- or D-, natural or unnat-

ural peptides containing 1-20 the same or different amino acids; ,

, , , ,


, , , ,

, , ,




, wherein ~ is the site of linkage; X_2, X_3, X_4, X_5, or X_6, are independently selected from NH; NHNH; $N(R_3)$; $N(R_3)N(R_{3'})$; O; S; C_1-C_6 of alkyl; C_2-C_6 of heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C_6 of aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or 1~8 amino acids; wherein R_3 is independently H;C_1-C_8 of alkyl; C_2-C_8 of hetero-alkyl, alkylcycloalkyl, heterocycloalkyl; C_6 of aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or 1-8 carbon atoms of esters, ether, or amide; or polyethyleneoxy unit of formula $(OCH_2CH_2)_p$ or $(OCH_2CH(CH_3))_p$, wherein p is an integer from 0 to about 1000, or combination above thereof.


7. The compound according to Claim **1, 2, 3,** or **4** wherein W may independently be composed of:
(A): a self-immolative spacer, peptidic units, a hydrazone, a disulfide, an ester, an amide, or a thioether bond. The self-immolative unit includes aromatic compounds that are electronically similar to the para-aminobenzyl-carbamoyl (PAB) groups, 2-aminoimidazol-5-methanol derivatives, heterocyclic PAB analogs, beta-glucuronide, and ortho or para-aminobenzylacetals; or one of the following structures:





;.



; or wherein the (*) atom is the point of attachment of another component; X^1, Y^1, Z^2 and Z^3 are independently NH, O, or S; Z^1 is independently H, NHR_1, OR_1, SR_1, COX_1R_1, wherein X_1 and R_1 are defined above; v is 0 or 1; U^1 is independently H, OH, C_1~C_6 alkyl, $(OCH_2CH_2)_n$, F, Cl, Br, I, OR_5, SR_5, NR_5R_5', N=NR_5, N=R_5, NR_5R_5', NO_2, SOR_5R_5', SO_2R_5, SO_3R_5, OSO_3R_5, PR_5R_5', POR_5R_5', $PO_2R_5R_5$', $OPO(OR_5)(OR_5')$, or $OCH_2PO(OR_5(OR_5')$, wherein R_5 and R_5' are independently selected from H, C_1~C_8 alkyl; C_2~C_8 alkenyl, alkynyl, heteroalkyl, or amino acid; C_6 aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl, or glycoside; or pharmaceutical cation salts.


8. The conjugate compound of Formula (I) according to Claim **1** having the following structures of a-16, a-20, a-21, a-39 to a-43, a-46, a-49, a-50, a-55, a-56, a-58 to a-62, a-66 to a-79, a-81 to a-93 :


a-16,



a-20,


a-21,



a-39,




a-40,




a-41,




a-42,




a-43,




a-46,




a-49,




a-50,




a-55,




a-56,




a-58,




a-59,




a-60,




a-61,




a-62,




a-66,




a-67,




a-68,




a-69,




a-70,




a-71,




a-72,




a-73,




a-74,




a-75,




a-76,




a-77,




a-78,




a-79,




a-81,




a-82,




a-83,




a-84,




a-85,




a-86,




a-87,




a-88,




a-89,




a-90,



a-91,



a-92,




a-93,


or their pharmaceutically acceptable salts, hydrates, or hydrated salts; or the polymorphic crystalline structures of these compounds; or their optical isomers, racemates, diastereomers or enantiomers; wherein mAb is an antibody or an antibody fragment that binds to a target cell~~a cell-binding molecule~~; ~~Z^3 and~~ Z^2 and Z^3 are independently H, OH, NH_2, O, NH, COOH, COO, C(O),C(O), C(O)NH, $C(O)NH_2$, R^{18}, $OCH_2OP(O)(OR^{18})_2$, $OC(O)OP(O)(OR^{18})_2$, $OPO(OR^{18})_2$, $NHPO(OR^{18})_2$, $OP(O)(OR^{18})O\text{-}P(O)(OR^{18})_2$, $OC(O)R^{18}$, $OC(O)NHR^{18}$, $OSO_2(OR^{18})$, O-(C_4-C_{12}-glycoside), of linear or branched alkyl or heteroalkyl; C_6 of linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 linear or branched of ~~aryl,~~ Ar-alkyl, heterocyclic, carbocyclic,

cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR^{17}), carbamate (-C(O)NR^{17}R^{18}); or polyalkylene glycols have a molecular weight of from about 88 Daltons to about 20 kDa; R^{17}and R^{18} are independently H, linear or branched alkyl or heteroalkyl; C_2-C_8 of linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 linear or branched of ~~aryl,~~ Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR^{17}), carbamate (-C(O)NR^{17}R^{18}); R^{19}is H, OH, NH_2, $OSO_2(OR^{18})$, $XCH_2OP(O)(OR^{18})_2$, $XPO(OR^{18})_2$, $XC(O)OP(O)(OR^{18})_2$, $XC(O)R^{18}$, $XC(O)NHR^{18}$, C_1~C_8 alkyl or carboxylate; C_2~C_8 alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C_6 aryl or alkylcarbonyl; or pharmaceutical salts; X_1, X_2 and X_3 are independently O, S, NH, NHNH, or CH_2; q_1 and q_2 are independently selected from 0-24; ~~p, p_1 and p_2 are~~is independently 1-100; ; Aa is natural or unnatural amino acid; r is 0-12; (Aa)r is a peptide containing the same or different sequence of amino acids when r >2; r=0 means (Aa)r absent; n is independently 1-30.

9. The conjugate compound of Formula (III) according to Claim **2** having the following structures of b-02 and b-15:




b-02,




b-15,

or their pharmaceutically acceptable salts, hydrates, or hydrated salts; or the polymorphic crystalline structures of these compounds; or their optical isomers, racemates, diastereomers or enantiomers; wherein mAb, ~~X_1,~~ X_2, ~~X_3,~~ p_1, p_2, ~~p_3, q_1, q_2, (Aa)$_r$, m,~~ and ~~n~~ Z^2 are described above.


10. The compound of Formula (IV) according to Claim **3** having the following structures:




c-06,




c-07




c-08,




c-09,




c-10,




c-11,




c-12,




c-13,




c-14,




c-15,




c-16,




c-17,




c-18,




c-19,




c-20,




c-21,




c-22,




c-23,




c-24,




c-25,




c-26,




c-27,




c-30,




c-31,




c-32,




c-33,




c-34,




c-35,




c-36,




c-37,




c-38,




c-39,




c-40,




c-41,




c-42,




c-43,




c-44,




c-45,




c-48,




c-49,




c-50,




c-51,




c-52,




c-53,




c-58,




c-59,




c-61,




c-62,




c-63,




c-64,




c-65,




c-68,




c-69,




c-70,




c-71,




c-72,




c-73,




c-74,




c-75,




c-76,




c-77,




c-78,




c-79,




c-80,




c-81,




c-82,




c-83,




c-84,




c-85,




c-86,




c-87,




c-88,




c-89,




c-90,




c-91,




c-92,




c-93,







c-95,




c-96,



c-97,




c-98,




c-99,

or their pharmaceutically acceptable salts, hydrates, or hydrated salts; or the polymorphic crystalline structures of these compounds; or their optical isomers, racemates, diastereomers or enantiomers; wherein X_1, X_2, X_3, Z_2, Z_3, p~~,~~ p_1, p_2, ~~p_3,~~ q_1, ~~q_2,~~ Lv_3, $(Aa)_r$, R_{25}, ~~$R_{25'}$,~~ and m are described above.


11. The compound of Formula (V) according to Claim **4** having the following structures of d-01, d-02 and d-14 to d-26:




d-01,




d-02,




d-14,




d-15,




d-16,




d-17,




d-18,




d-19,




d-20,




d-21,




d-22,




d-23,



d-24,



d-25,



d-26,

wherein X_1, X_2, X_3, Z_2, Z_3, p. p_1, p_2, p_3, q_1, q_2, Lv_3, $(Aa)_r$, R_{25}, $R_{25'}$, and m are described above.

12. The compound according to Claim **1, 2, 8,** or **9,** wherein the cell binding agent/molecule is selected from:

~~**(A):** the group consisting of an antibody, a protein, probody, nanobody, a vitamin (including folate), peptides, a polymeric micelle, a liposome, a lipoprotein-based drug carrier, a nano-particle drug carrier, a dendrimer, and a molecule or a particle said above coating or linking with a cell-binding ligand, or a combination of said above thereof;~~


~~**(B):** an antibody-like protein,~~ a full-length antibody (polyclonal antibody, monoclonal antibody, antibody dimer, antibody multimer), multispecific antibody (selected from, bispecific antibody, trispecific antibody, or tetraspecific antibody); a single chain antibody, an antibody fragment

that binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment that binds the target cell, a chimeric antibody, a chimeric antibody fragment that binds to the target cell, a domain antibody, a domain antibody fragment that binds to the target cell, a resurfaced antibody, a resurfaced single chain antibody, or a resurfaced antibody fragment that binds to the target cell, a humanized antibody or a resurfaced antibody, a humanized single chain antibody, or a humanized antibody fragment that binds to the target cell, anti-idiotypic (anti-Id) antibodies, CDR's, diabody, triabody, tetrabody, miniantibody, a probody~~,~~ and a probody fragment~~, small immune proteins (SIP), a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, a nutrient transport molecule, large molecular weight proteins, fusion proteins, kinase inhibitors, gene targeting agents, nanoparticles or polymers modified with antibodies or large molecular weight proteins;~~


~~**(C):** a cell-binding ligand or receptor agonist selected from: Folate derivatives; Glutamic acid urea derivatives; Somatostatin and its analogs (selected from the group consisting of octreotide (Sandostatin) and lanreotide (Somatuline)); Aromatic sulfonamides; Pituitary adenylate cyclase activating peptides (PACAP) (PAC1); Vasoactive intestinal peptides (VIP/PACAP) (VPAC1, VPAC2); Melanocyte stimulating hormones (α-MSH); Cholecystokinins (CCK) /gastrin receptor agonists; Bombesins (selected from the group consisting ofPyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met NH_2)/gastrin-releasing peptide (GRP); Neurotensin receptor ligands (NTR1, NTR2, NTR3); Substance P (NK1 receptor) ligands; Neuropeptide Y (Y1–Y6); Homing Peptides include RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), the dimeric and multimeric cyclic RGD peptides (selected from cRGDfV), TAASGVRSMH and LTLRWVGLMS (Chondroitin sulfate proteoglycan NG2 receptor ligands) and F3 peptides; Cell Penetrating Peptides (CPPs); Peptide Hormones, selected from the group consisting of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists, and gonadotropin-releasing hormone (GnRH) agonist, acts by targeting follicle stimulating hormone (FSH) and luteinizing hormone (LH), as well as testosterone production, selected from the group consisting of buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), Gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH_2), Goserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH_2), Histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), Nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH_2), Triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH_2), Nafarelin, Deslorelin, Abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH_2), Cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH_2), Degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carba-moyl)-Leu-isopropylLys-Pro-D-Ala-NH_2), and Ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-~~

Ser-Tyr-D-(N9, N10-diethyl)-homoArg-Leu-(N9, N10-diethyl)-homoArg-Pro-D-Ala-NH_2); Pattern Recognition Receptor (PRRs), selected from the group consisting of Toll-like receptors' (TLRs) ligands, C-type lectins and Nodlike Receptors' (NLRs) ligands; Calcitonin receptor agonists; integrin receptors' and their receptor subtypes' (selected from the group consisting of$\alpha_v\beta_1$, $\alpha_v\beta_3$, $\alpha_v\beta_5$, $\alpha_v\beta_6$, $\alpha_6\beta_4$, $\alpha_7\beta_1$, $\alpha_L\beta_2$, $\alpha_{IIb}\beta_3$) agonists (selected from the group consisting of GRGDSPK, cyclo(RGDfV) (L1) and its derives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)f-V), cyclo(RGDf-N(Me)V-)(Cilengitide)]; Nanobody (a derivative of VHH (camelid Ig)); Domain antibodies (dAb, a derivative of VH or VL domain); Bispecific T cell Engager (BiTE, a bispecific diabody); Dual-Affinity ReTargeting (DART, a bispecific diabody); Tetravalent tandem antibodies (TandAb, a dimerized bispecific diabody); Anticalin (a derivative of Lipocalins); Adnectins (10th FN3 (Fibronectin)); Designed Ankyrin Repeat Proteins (DARPins); Avimers; EGF receptors, or VEGF receptors' agonists;


(D): A small molecule of cell-binding molecule/ligand or a cell receptor agonist selected from the following: LB01 (Folate), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (Somatostatin), LB06 (Somatostatin), LB07 (Octreotide, a Somatostatin analog), LB08 (Lanreotide, a Somatostatin analog), LB09 (Vapreotide (Sanvar) , a Somatostatin analog), LB10 (CAIX ligand), LB11 (CAIX ligand), LB12 (Gastrin releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone-releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone-releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, Abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (for $\alpha_v\beta_3$ integrin receptor, cyclic RGD pentapeptide), LB19 (hetero-bivalent peptide ligand for VEGF receptor), LB20 (Neuromedin B), LB21 (bombesin for a G-protein coupled receptor), LB22 (TLR_2 for a Toll-like receptor,), LB23 (for an androgen receptor), LB24 (Cilengitide/cyclo(-RGDfV-) for an α_v integrin receptor, LB23 (Fludrocortisone), LB25 (Rifabutin analog), LB26 (Rifabutin analog), LB27 (Rifabutin analog), LB28 (Fludrocortisone), LB29 (Dexamethasone), LB30 (fluticasone propionate), LB31 (Beclometasone dipropionate), LB32 (Triamcinolone acetonide), LB33 (Prednisone), LB34 (Prednisolone), LB35 (Methylprednisolone), LB36 (Betamethasone), LB37 (Irinotecan analog), LB38 (Crizotinib analog), LB39 (Bortezomib analog), LB40 (Carfilzomib analog), LB41 (Carfilzomib analog), LB42 (Leuprolide analog), LB43 (Triptorelin analog), LB44 (Clindamycin), LB45 (Liraglutide analog), LB46 (Semaglutide analog), LB47 (Retapamulin analog), LB48 (Indibulin analog), LB49 (Vinblastine analog), LB50 (Lixisenatide analog), LB51 (Osimertinib analog), LB52 (a nucleoside analog), LB53 (Erlotinib analog) or LB54 (Lapatinib analog) which are shown in the following structures:




~~LB01 (Folate conjugate),~~




~~LB02 (PMSA ligand conjugate),~~




~~LB03 (PMSA ligand conjugate),~~




~~LB04 (PMSA ligand),~~




~~LB05 (Somatostatin),~~




~~LB06 (Somatostatin),~~




~~LB07 (Octreotide, a Somatostatin analog),~~




~~LB08 (Lanreotide, a Somatostatin analog),~~




~~LB09 (Vapreotide (Sanvar), a Somatostatin analog),~~




~~LB10 (CAIX ligand),~~




~~LB11 (CAIX ligand),~~




~~LB12 (Gastrin releasing peptide receptor (GRPr), MBA),~~




~~LB13 (luteinizing hormone-releasing hormone (LH-RH) ligand and GnRH),~~




~~LB14 (luteinizing hormone-releasing hormone (LH-RH) and GnRH ligand),~~




~~LB15 (GnRH antagonist, Abarelix),~~




~~LB16 (cobalamin, vitamin B12 analog),~~



~~LB17 (cobalamin, vitamin B12 analog),~~



~~LB18 (for $\alpha_v\beta_3$ integrin receptor, cyclic RGD pentapeptide),~~




~~LB19 (hetero-bivalent peptide ligand conjugate for VEGF receptor),~~




~~LB20 (Neuromedin B),~~

~~Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met~~


~~LB21 (bombesin conjugate for a G-protein coupled receptor),~~




~~LB22 (TLR_2 conjugate for a Toll-like receptor),~~




~~LB23 (an androgen receptor),~~




~~LB24 (Cilengitide/cyclo(-RGDfV-) conjugate for an α_v integrin receptor)~~




~~LB25 (Rifabutin analog),~~




~~LB26 (Rifabutin analog),~~




~~LB27 (Rifabutin analog),~~




~~LB28 (Fludrocortisone),~~




~~LB29 (Dexamethasone),~~




~~LB30 (fluticasone propionate),~~




~~LB31 (Beclometasone dipropionate),~~




~~LB32 (Triamcinolone acetonide),~~




~~LB33 (Prednisone),~~




~~LB34 (Prednisolone),~~




~~LB35 (Methylprednisolone),~~




~~LB36 (Betamethasone),~~




~~LB37 (Irinotecan analog),~~




~~LB38 (Crizotinib analog),~~




~~LB39 (Bortezomib analog), wherein Y_5, is N, CH, C(Cl), C(CH_3), or C($COOR_4$); R_4 is H, C_1-C_6 Alkyl, C_3-C_8 Ar;~~




~~LB40 (Carfilzomib analog),~~




~~LB41 (Carfilzomib analog),~~




~~LB42 (Leuprolide analog),~~




~~LB43 (Triptorelin analog),~~




~~LB44 (Clindamycin),~~




~~LB45 (Liraglutide analog),~~




~~LB46 (Semaglutide analog),~~




~~LB47 (Retapamulin analog),~~




~~LB48 (Indibulin analog),~~




~~LB49 (Vinblastine analog),~~




~~LB50 (Lixisenatide analog),~~




~~LB51 (Osimertinib analog),~~



~~LB52 (a nucleoside analog),~~





























~~LB53 (Erlotinib analog),~~




~~LB54 (Lapatinib analog),~~

~~wherein "~~~~" is the site to link the side chain linker of the present patent; X_4,and Y_1 are independently O, NH, NHNH, NR_1, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, $OC(O)N(R_1)$, $N(R_1)C(O)N(R_1)$, CH_2, C(O)NHNHC(O) and $C(O)NR_1$; X_1 is H, CH_2, OH, O, C(O), C(O)NH, $C(O)N(R_1)$, R_1, NHR_1, NR_1, $C(O)R_1$ or C(O)O; X_5 is H, CH_3, F, or Cl; M_1 and M_2 are independently H, Na, K, Ca, Mg, NH_4, $N(R_1R_2R_3R_4)$; R_1, R_2, R_3 and R_4 are defined in Claim 1.~~

13. The compound according to Claim **1**, or **2** or **12**, wherein the cell-binding molecule, T, when linking to V_1 of Formula (I) and (III) when v_2 is 0; or, linking to V_2 of Formula (I) and (III); or, when T is directly linking to L_1 of Formula (I) and (III) whernV_1, is absent and v_2 is 0; or, when T is directly linking to L_2 of Formula (I) and (III) when V_2, is absent, having one or more of the following the linkage structures:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



, , wherein R^{20} and R^{21} are independently C_1~C_8 alkyl; C_2~C_8 heteroalkyl, or heterocyclic; C_6 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocyclic, or alkylcarbonyl; or C_2-C_{100} polyethylene glycol having formula of $(CH_2CH_2O)_p$.

14. The compound according to Claim **1, 2, 8,** or **9,** wherein the cell binding agent/molecule is capable of targeting against a tumor cell, a virus infected cell, a microorganism infected cell, a parasite infected cell, an autoimmune disease cell, an activated tumor cells, a myeloid cell, an activated

T-cell, an affecting B cell, or a melanocyte, or any cells expressing any one of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e，CD2, CD3, CD3d, CD3e, CD3g, CD4，CD5，CD6，CD7，CD8，CD8a, CD8b, CD9，CD10，CD11a，CD11b，CD11c，CD11d，CD12w，CD14，CD15，CD16，CD16a, CD16b, CDw17，CD18，CD19, CD20, CD21, CD22，CD23，CD24，CD25，CD26，CD27，CD28，CD29，CD30, CD31，CD32，CD32a，CD32b, CD33, CD34，CD35，CD36，CD37，CD38, CD39, CD40, CD41，CD42，CD42a，CD42b, CD42c, CD42d, CD43，CD44，CD45，CD46，CD47，CD48，CD49b，CD49c，CD49c, CD49d, CD49f, CD50, CD51, CD52, CD53，CD54，CD55，CD56, CD57, CD58，CD59，CD60, CD60a, CD60b, CD60c, CD61，CD62E，CD62L，CD62P，CD63，CD64，CD65, CD65s, CD66, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD67, CD68，CD69，CD70, CD71，CD72，CD73, CD74, CD75, CD75s, CD76, CD77, CD78, CD79，CD79a，CD79b，CD80, CD81，CD82，CD83，CD84, CD85, CD85a, CD85b, CD85c, CD85d, CD85e，CD85f, CD85g, CD85g, CD85i, CD85j, CD85k, CD85m, CD86，CD87，CD88，CD89，CD90，CD91，CD92, CD93, CD94, CD95，CD96，CD97, CD98, CD99, CD100，CD101, CD102，CD103, CD104，CD105，CD106，CD107, CD107a, CD107b, CD108, CD109，CD110, CD111，CD112, CD113, CD114, CD115，CD116，CD117, CD118, CD119, CD120，CD120a，CD120b, CD121，CD121a, CD121b, CD122，CD123, CD123a，CD124, CD125, CD126，CD127, CD128, CD129, CD130, CD131，CD132, CD133，CD134，CD135，CD136, CD137，CD138, CD139，CD140，CD140a, CD140b, CD141，CD142，CD143，CD144，CD145，CDw145, CD146, CD147，CD148，CD149, CD150，CD151，CD152，CD153, CD154，CD155，CD156，CD156a, CD156b, CD156c, CD156d, CD157, CD158，CD158a，CD158b1，CD158b2，CD158c，CD158d，CD158e1，CD158e2，CD158f2，CD158g，CD158h，CD158i，CD158j，CD158k，CD159，CD159a，CD159b，CD159c，CD160, CD161，CD162, CD163，CD164，CD165, CD166，CD167, CD167a, CD167b, CD168，CD169，CD170，CD171，CD172, CD172a, CD172b, CD172g, CD173，CD174，CD175, CD175s, CD176，CD177, CD178，CD179，CD179a，CD179b，CD180，CD181，CD182, CD183，CD184，CD185, CD186，CDw186，CD187, CD188，CD189，CD190，CD191，CD192, CD193，CD194，CD195，CD196，CD197, CD198，CD199，CDw198，CDw199，CD200，CD201，CD202, CD202（a，b），CD203，CD203c，CD204，CD205, CD206，CD207, CD208，CD209，CD210，CDw210a，CDw210b，CD211，CD212, CD213，CD213a1，CD213a2，CD214，CD215，CD216，CD217, CD218，CD218a，CD218，CD21b9，CD220，CD221，CD222, CD223，

CD224，CD225, CD226，CD227, CD228，CD229，CD230，CD231，CD232, CD233，CD234，CD235, CD235a，CD235b，CD236，CD237, CD238，CD239，CD240，CD240ce，CD240d，CD241，CD242, CD243，CD244，CD245, CD246，CD247, CD248，CD249，CD250，CD251，CD252, CD253，CD254，CD255, CD256，CD257, CD258，CD259，CD260，CD261，CD262, CD263，CD264，CD265, CD266，CD267, CD268，CD269，CD270，CD271，CD272, CD273，CD274，CD275, CD276，CD277, CD278，CD279，CD281，CD282, CD283，CD284，CD285, CD286，CD287, CD288，CD289，CD290，CD291，CD292, CD293，CD294，CD295, CD296，CD297, CD298，CD299，CD300，CD300a，CD300b，CD300c，CD301，CD302, CD303，CD304，CD305, CD306，CD307，CD307a, CD307b, CD307c, CD307d, CD307e, CD307f, CD308，CD309，CD310，CD311，CD312, CD313，CD314，CD315, CD316，CD317, CD318，CD319，CD320，CD321，CD322, CD323，CD324，CD325, CD326，CD327, CD328，CD329，CD330，CD331，CD332, CD333，CD334，CD335, CD336，CD337, CD338，CD339，CD340，CD341，CD342, CD343，CD344，CD345, CD346，CD347, CD348，CD349，CD350，CD351，CD352, CD353，CD354，CD355, CD356，CD357, CD358，CD359，CD360，CD361，CD362, CD363，CD364，CD365, CD366，CD367, CD368，CD369，CD370，CD371，CD372, CD373，CD374，CD375, CD376，CD377, CD378，CD379，CD381，CD382, CD383，CD384，CD385, CD386, CD387, CD388，CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB，APO2，ASLG659，BMPR1B, 4-1BB, 5AC，5T4 (Trophoblastic glycoprotein, TPBG, 5T4, Wnt-Activated Inhibitory Factor 1 or WAIF1), Adenocarcinoma antigen, AGS-5, AGS-22M6, Activin receptor-like kinase 1, AFP, AKAP-4, ALK, Alpha integrin, Alpha v beta6, Amino-peptidase N, Amyloid beta, Androgen receptor, Angiopoietin 2, Angiopoietin 3, Annexin A1, Anthrax toxin protective antigen, Anti-transferrin receptor, AOC3 (VAP-1), B7-H3, Bacillus anthracis anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cell, bcr-abl, Bombesin, BORIS, C5, C242 antigen, CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, Canis lupus familiaris IL31, Carbonic anhydrase IX, Cardiac myosin, CCL11(C-C motif chemokine 11), CCR4 (C-C chemokine receptor type 4), CCR5, CD3E (epsilon), CEA (Carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (Factor D), Ch4D5, Cholecystokinin 2 (CCK2R), CLDN18 (Claudin-18), Clumping factor A, cMet, CRIPTO, FCSF1R (Colony stimulating factor 1 receptor), CSF2 (colony stimulating factor 2, Granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, C-X-

C chemokine receptor type 4, cyclic ADP ribose hydrolase, Cyclin B1, CYP1B1, Cytomegalovirus, Cytomegalovirus glycoprotein B, Dabigatran, DLL3 (delta-like-ligand 3), DLL4 (delta-like-ligand 4), DPP4 (Dipeptidyl-peptidase 4), DR5 (Death receptor 5), E. coli shiga toxin type-1, E. coli shiga toxin type-2, ED-B, EGFL7 (EGF-like domain-containing protein 7), EGFR, EGFRII, EGFRvIII, Endoglin, Endothelin B receptor, Endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, Episialin, ERBB2 (Epidermal Growth Factor Receptor 2), ERBB3, ERG (TMPRSS2 ETS fusion gene), Escherichia coli, ETV6-AML, FAP (Fibroblast activation protein alpha), FCGR1, alpha-Fetoprotein, Fibrin II, beta chain, Fibronectin extra domain-B, FOLR (folate receptor), Folate receptor alpha, Folate hydrolase, Fos-related antigen 1F protein of respiratory syncytial virus, Frizzled receptor, Fucosyl GM1, GD2 ganglioside, G-28 (a cell surface antigen glyvolipid), GD3 idiotype, GloboH, Glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α-chain, Growth differentiation factor 8, GP100, GPNMB (Trans-membrane glycoprotein NMB), GUCY2C (Guanylate cyclase 2C, guanylyl cyclase C(GC-C), intestinal Guanylate cyclase, Guanylate cyclase-C receptor, Heat-stable enterotoxin receptor (hSTAR)), Heat shock proteins, Hemagglutinin, Hepatitis B surface antigen, Hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2/neu, HER3 (ERBB-3), IgG4, HGF/SF (Hepatocyte growth factor/scatter factor), HHGFR, HIV-1, Histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB , HMW-MAA, Human chorionic gonadotropin, HNGF, Human scatter factor receptor kinase, HPV E6/E7, Hsp90, hTERT, ICAM-1 (Intercellular Adhesion Molecule 1), Idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, Influenza hemagglutinin, IgE, IgE Fc region, IGHE, interleukins (comprising IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-27, or IL-28), IL31RA, ILGF2 (Insulin-like growth factor 2), Integrins (α4, $\alpha_{IIb}\beta_3$, αvβ3, $\alpha_4\beta_7$, α5β1, α6β4, α7β7, αllβ3, α5β5, αvβ5), Interferon gamma-induced protein, ITGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, Legumain, Lewis-Y antigen, LFA-1 (Lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, Lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGE A1, MAGE A3, MAGE 4, MART1, MCP-1, MIF (Macrophage migration inhibitory factor, or glycosylation-inhibiting factor (GIF)), MS4A1 (membrane-spanning 4-domains subfamily A member 1), MSLN (mesothelin), MUC1(Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)), MUC1-KLH, MUC16 (CA125), MCP1(monocyte chemotactic protein 1), MelanA/MART1, ML-IAP, MPG, MS4A1 (membrane-spanning 4-domains subfamily A), MYCN, Myelin-associated glycoprotein, Myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, Neural apoptosis-regulated proteinase 1, NOGO-A, Notch receptor, Nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (Oxidized low-density lipoprotein), OY-TES1, P21, p53 nonmutant, P97, Page4, PAP, Paratope of anti-(N-

glycolylneuraminic acid), PAX3, PAX5, PCSK9, PDCD1 (PD-1, Programmed cell death protein 1), PDGF-Rα (Alpha-type platelet-derived growth factor receptor), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, Platelet-derived growth factor receptor beta, Phosphate-sodium co-transporter, PMEL 17, Polysialic acid, Proteinase3 (PR1), Prostatic carcinoma, PS (Phosphatidylserine), Prostatic carcinoma cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, Rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), Rhesus factor, RANKL, RhoC, Ras mutant, RGS5, ROBO4, Respiratory syncytial virus, RON, ROR1, Sarcoma translocation breakpoints, SART3, Sclerostin, SLAMF7 (SLAM family member 7), Selectin P, SDC1 (Syndecan 1), sLe(a), Somatomedin C, SIP (Sphingosine-1-phosphate), Somatostatin, Sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial antigen of the prostate 1), STEAP2, STn, TAG-72 (tumor associated glycoprotein 72), Survivin, T-cell receptor, T cell transmembrane protein, TEM1 (Tumor endothelial marker 1), TENB2, Tenascin C (TN-C), TGF-α, TGF-β (Transforming growth factor beta), TGF-β1, TGF-β2 (Transforming growth factor-beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), Tn, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF-13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (Tumor necrosis apoptosis Inducing ligand Receptor 1), TRAILR2 (Death receptor 5 (DR5)), tumor-associated calcium signal transducer 2, tumor specific glycosylation of MUC1, TWEAK receptor, TYRP1(glycoprotein 75), TRP-2, Tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE 1, or cells expressing any insulin growth factor receptors, or any epidermal growth factor receptors.

15. The compound according to Claim **14**, wherein the tumor cell is selected from the group consisting of lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, none small-cell lung cancer cells, testicular cancer cells, malignant cells, or any cells that grow and divide at an unregulated, quickened pace to cause cancers.

16. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate compounds of any one of Claim **1, 2, 8,** or **9,** and a pharmaceutically acceptable salt, carrier, diluent, or excipient therefore, or a combination of the conjugates thereof, for use in the treatment or prevention of a cancer.

17. Thepharmaceutical composition for use according to Claim **16**, wherein the pharmaceutical composition is either in the liquid formula or in the formulated lyophilized solid, comprising by weight of: 0.01%-99% of one or more conjugates of any one of Claim **1, 2, 8,** or **9**; 0.0%-20.0% of

one or more polyols; 0.0%-2.0% of one or more surfactants; 0.0% -5.0% of one or more preservatives; 0.0% -30% of one or more amino acids; 0.0% -5.0% of one or more antioxidants; 0.0% -0.3% of one or more metal chelating agents; 0.0% -30.0% of one or more buffer salts for adjusting pH of the formulation to pH 4.5 to 7.5; and 0.0% -30.0% of one or more of isotonic agent for adjusting osmotic pressure bewteen ~~about~~ 250 to 350 mOsm when reconstituted for administration to a patient;

wherein the polyol is selected from fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, sucrose, trehalose, sorbose, melezitose, raffinose, mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, threitol, sorbitol, glycerol, or L-gluconate and its metallic salts);

wherein the surfactant is selected from polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, or polysorbate 85, poloxamer, poly(ethylene oxide)-poly(propylene oxide), polyethylene-polypropylene, Triton; sodium dodecyl sulfate (SDS), sodium laurel sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine and coco ampho glycinate; or isostearyl ethylimidonium ethosulfate; polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol;

wherein the preservative is selected from benzyl alcohol, octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol;

wherein the amino acid is selected from arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycine glutamic acid or aspartic acid;

wherein the antioxidant is selected from ascorbic acid, glutathione, cystine or and methionine;

wherein the chelating agent is selected from EDTA or EGTA;

wherein the buffer salt is selected from sodium, potassium, ammonium, or trihydroxyethylamino salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid or phthalic acid; Tris or tromethamine hydrochloride, phosphate or sulfate; arginine, glycine, glycylglycine, or histidine with anionic acetate, chloride, phosphate, sulfate, or succinate salts;

wherein the tonicity agent is selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or sodium chloride.

18. The pharmaceutical composition for use according to Claim **16** or **17,** is packed in a vial, bottle, pre-filled syringe, or pre-filled auto-injector syringe, in a form of a liquid or lyophilized solid.

19. The compound of Claim **1, 2, 8, 9,** or in the form of the pharmaceutical composition of Claim **16** or **17,** wherein the conjugate hasin vitro, in vivo or ex vivo cell killing activity.

20. A pharmaceutical composition according to Claim **16** or **17,** wherein the pharmaceutical composition is administered concurrently with a chemotherapeutic agent, a radiation therapy, an immunotherapy agent, an autoimmune disorder agent, an anti-infectious agents or the other conjugates for use in the synergistical treatment or prevention of a cancer.

21. The pharmaceutical composition according to Claim **20,** the agent(s) or therapy or conjugates~~wherein the chemotherapeutic agent~~ is selected from:

(1). A chemotherapeutic agent :~~(1).~~

a). an alkylating agent: selected from nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, novembichin, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and adozelesin, carzelesin, bizelesin or their synthetic analogues; duocarmycin and its synthetic analogues, KW-2189, CBI-TMI, or CBI dimers; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers, imidazobenzothiadiazepine dimers, or oxazolidinobenzodiazepine dimers; Nitrosoureas: comprising carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; Alkylsulphonates: including busulfan, treosulfan, improsulfan and piposulfan); Triazenes or dacarbazine; Platinum containing compounds: comprising carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, meturedopa, or uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine];

b). A plant alkaloid: selected from the group consisting of Vinca alkaloids: including vincristine, vinblastine, vindesine, vinorelbine, and navelbin; Taxoids: comprising paclitaxel, docetaxol and their analogs, Maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, ansamitocins and their analogs, cryptophycins (including the group of cryptophycin 1 and cryptophycin 8); epothilones, eleutherobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, cephalostatins; pancratistatin; a sarcodictyin; spongistatin;

c). A DNA Topoisomerase Inhibitor: selected from the groups of Epipodophyllins: comprising 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acids (or retinols), teniposide, topotecan, 9-nitrocamptothecin or RFS 2000; and mitomycins and their analogs;

d). An antimetabolite: selected from the group consisting of {[Anti-folate: (DHFR inhibitors: comprising methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid) or folic acid analogues); IMP dehydrogenase Inhibitors: (including mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase Inhibitors: (including hydroxyurea, deferoxamine)]; [Pyrimidine analogs: Uracil analogs: (including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-Fluorouracil, floxuridine, raltitrexed); Cytosine analogs: (including cytarabine, cytosine arabinoside, fludarabine); Purine analogs: (including azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine)]; folic acid replenisher, frolinic acid};

e). A hormonal therapy: selected from Receptor antagonists: [Anti-estrogen: (including megestrol, raloxifene, tamoxifen); LHRH agonists: (including goscrclin, leuprolide acetate); Anti-androgens: (including bicalutamide, flutamide, calusterone, dromostanolone propionate, epitiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane and other androgens inhibitors)]; Retinoids/Deltoids: [Vitamin D3 analogs: (including CB 1093, EB 1089 KH 1060, cholecalciferol, ergocalciferol); Photodynamic therapies: (including verteporfin, phthalocyanine, photosensitizer Pc4, demethoxyhypocrellin A); Cytokines: (comprising Interferon-alpha, Interferon-gamma, tumor necrosis factor (TNFs), human proteins containing a TNF domain)]};

f). A kinase inhibitor, selected from the group consisting of BIBW 2992 (anti-EGFR/Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib. vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, Trastuzumab, Ranibizumab, Panitumumab, ispinesib;

g). A poly (ADP-ribose) polymerase (PARP) inhibitors selected from the group of olaparib, niraparib, iniparib, talazoparib, veliparib, CEP 9722 (Cephalon's), E7016 (Eisai's), BGB-290 (BeiGene's), or 3-aminobenzamide.

h). An antibiotic, selected from the group consisting of an enediyne antibiotic (selected from the group of calicheamicin, calicheamicin γ1, δ1, α1 or β1; dynemicin, including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, or neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomycins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin,

morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin, epirubicin, eribulin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;

i). A polyketide (acetogenin), bullatacin and bullatacinone; gemcitabine, epoxomicins and-carfilzomib, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, Xegeva, Provenge, Yervoy, Isoprenylation inhibitors and Lovastatin, Dopaminergic neurotoxins and1-methyl-4-phenylpyridinium ion, Cell cycle inhibitors (including staurosporine), Actinomycins (including Actinomycin D, dactinomycin), amanitins, Bleomycins (including bleomycin A2, bleomycin B2, peplomycin), Anthracyclines (including daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, zorubicin, mtoxantrone, MDR inhibitors or verapamil, Ca^{2+}ATPase inhibitors or thapsigargin, Histone deacetylase inhibitors ((including Vorinostat, Romidepsin, Panobinostat, Valproic acid, Mocetinostat (MGCD0103), Belinostat, PCI-24781, Entinostat, SB939, Resminostat, Givinostat, AR-42, CUDC-101, sulforaphane, Trichostatin A); Thapsigargin, Celecoxib, glitazones, epigallocatechin gallate, Disulfiram, Salinosporamide A.; Anti-adrenals, selected from the group of aminoglutethimide, mitotane, trilostane; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; eflornithine (DFMO), elfomithine; elliptinium acetate, etoglucid; gallium nitrate; gacytosine, hydroxyurea; ibandronate, lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2',2"-trichlorotriethylamine; trichothecenes (including the group of T-2 toxin, verrucarin A, roridin A and anguidine); urethane, siRNA, antisense drugs;

(2). An anti-autoimmune disease agent: cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticosteroids (including the group consisting of amcinonide**,** betamethasone, budesonide**,** hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, Triamcinolone acetonide, beclometasone dipropionate), DHEA, enanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenylate, prednisone, sirolimus, tacrolimus.

(3). An anti-infectious disease agents comprising:

a). Aminoglycosides: amikacin, astromicin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycetin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamicin;

b). Amphenicols: azidamfenicol, chloramphenicol, florfenicol, thiamphenicol;

c). Ansamycins: geldanamycin, herbimycin;

d). Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem**,** panipenem;

e). Cephems: carbacephem (loracarbef), cefacetrile, cefaclor, cefradine, cefadroxil, cefalonium, cefaloridine, cefalotin or cefalothin, cefalexin, cefaloglycin, cefamandole, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, cefetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprole, ceftriaxone, cefuroxime, cefuzonam, cephamycin (including cefoxitin, cefotetan, cefmetazole), oxacephem (flomoxef, latamoxef);

f). Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin;

g). Glycylcyclines: tigecycline;

h). β-Lactamase inhibitors: penam (sulbactam, tazobactam), clavam (clavulanic acid);

i). Lincosamides: clindamycin, lincomycin;

j). Lipopeptides: daptomycin, A54145, calcium-dependent antibiotics (CDA);

k). Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolide (telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin;

l). Monobactams: aztreonam, tigemonam;

m). Oxazolidinones: linezolid;

n). Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam)**,** mezlocillin, meticillin, nafcillin, oxacillin, penamecillin, penicillin, pheneticillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin;

o). Polypeptides: bacitracin, colistin, polymyxin B;

p). Quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, kano trovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin,

orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin;

q). Streptogramins: pristinamycin, quinupristin/dalfopristin;

r). Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilimide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole);

s). Steroid antibacterials: selected from fusidic acid;

t). Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, metacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (including tigecycline);

u). Other antibiotics: selected from the group consisting of annonacin, arsphenamine, bactoprenol inhibitors (Bacitracin), DADAL/AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin/dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;

(4). Anti-viral drugs comprising:

a). Entry/fusion inhibitors: aplaviroc, maraviroc, vicriviroc, *gp41* (enfuvirtide**),** PRO 140**,** CD4 (ibalizumab);

b). Integrase inhibitors: raltegravir, elvitegravir, globoidnan A;

c). Maturation inhibitors: bevirimat, vivecon;

d). Neuraminidase inhibitors**:** oseltamivir, zanamivir, peramivir;

e). Nucleosides & nucleotides: abacavir, aciclovir, adefovir, amdoxovir, apricitabine, brivudine, cidofovir, clevudine, dexelvucitabine, didanosine (ddI), elvucitabine, emtricitabine (FTC), entecavir, famciclovir, fluorouracil (5-FU), 3'-fluoro-substituted 2', 3'-dideoxynucleoside analogues (including the group consisting of3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'-dideoxyguanosine (FLG), fomivirsen, ganciclovir**,** idoxuridine, lamivudine (3TC), l-nucleosides (including the group consisting of *β*-l-thymidine and *β*-l-2'-deoxycytidine), penciclovir, racivir, ribavirin, stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine valaciclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT);

f). Non-nucleosides: amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine)**,** delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphonoformic acid), imiquimod, interferon alfa, loviride, lodenosine, methisazone, nevirapine, NOV-205, peginterferon alfa, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine;

g). Protease inhibitors: amprenavir**,** atazanavir**,** boceprevir, darunavir, fosamprenavir**,** indinavir, lopinavir**,** nelfinavir, pleconaril, ritonavir**,** saquinavir**,** telaprevir (VX-950), tipranavir;

h). Other types of anti-virus drugs: abzyme**,** arbidol, calanolide a, ceragenin, cyanovirin-n, diarylpyrimidines, epigallocatechin gallate (EGCG)**,** foscarnet**,** griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib.

(5). The pharmaceutically acceptable salts, acids, derivatives, hydrate or hydrated salt; or a crystalline structure; or an optical isomer, racemate, diastereomer or enantiomer of any of the above drugs.

22. The pharmaceutical composition for use according to claim 20~~The compound according to Claim 19~~, wherein the other conjugates for use in the synergistical treatment or prevention of a cancer are selected from one or several of the following drugs: Abatacept, abemaciclib, Abiraterone acetate, Abraxane, Acetaminophen/hydrocodone, Acalabrutinib, aducanumab, Adalimumab, ADXS31-142, ADXS-HER2, afatinib dimaleate, aldesleukin, alectinib, alemtuzumab, Alitretinoin, ado-trastuzumab emtansine, Amphetamine/ dextroamphetamine, anastrozole, Aripiprazole, anthracyclines, Aripiprazole, Atazanavir, Atezolizumab, Atorvastatin, Avelumab, Axicabtagene ciloleucel, axitinib, belinostat, BCG Live, Bevacizumab, bexarotene, blinatumomab, Bortezomib, bosutinib, brentuximab vedotin, brigatinib, Budesonide, Budesonide/ formoterol, Buprenorphine, Cabazitaxel, Cabozantinib, capmatinib, Capecitabine, carfilzomib, chimeric antigen receptor-engineered T (CAR-T) cells, Celecoxib, ceritinib, Cetuximab, Chidamide, Ciclosporin, Cinacalcet, crizotinib, Cobimetinib, Cosentyx, crizotinib, CTL019, Dabigatran, dabrafenib, dacarbazine, daclizumab, dacomotinib, daptomycin, Daratumumab, Darbepoetin alfa, Darunavir, dasatinib, denileukin diftitox, Denosumab, Depakote, Dexlansoprazole, Dexmethylphenidate, Dexamethasone, DigniCap Cooling System, Dinutuximab, Doxycycline, Duloxetine, Duvelisib, durvalumab, elotuzumab, Emtricibine/Rilpivirine/Tenofovir, disoproxil fumarate, Emtricitbine/tenofovir/efavirenz, Enoxaparin, ensartinib, Enzalutamide, Epoetin alfa, erlotinib, Esomeprazole, Eszopiclone, Etanercept, Everolimus, exemestane, everolimus, exenatide ER, Ezetimibe, Ezetimibe/simvastatin, Fenofibrate, Filgrastim, fingolimod, Fluticasone propionate, Fluticasone/salmeterol, fulvestrant, gazyva, gefitinib, Glatiramer, Goserelin acetate, Icotinib, Imatinib, Ibritumomab tiuxetan, ibrutinib, idelalisib, ifosfamide, Infliximab, imiquimod, ImmuCyst, Immuno BCG, iniparib, Insulin aspart, Insulin detemir, Insulin glargine, Insulin lispro, Interferon alfa, Interferon alfa-1b, Interferon alfa-2a, Interferon alfa-2b, Interferon beta, Interferon beta 1a, Interferon beta 1b, Interferon gamma-1a, lapatinib, Ipilimumab, Ipratropium bromide/ salbutamol, Ixazomib, Kanuma, Lanreotide acetate, lenalidomide, lenaliomide, lenvatinib mesylate, letrozole, Levothyroxine, Levothyroxine, Lidocaine, Linezolid, Liraglutide, Lisdexamfetamine, LN-144, lorlatinib, Memantine, Methylphenidate,

Metoprolol, Mekinist, mericitabine/ Rilpivirine/Tenofovir, Modafinil, Mometasone, Mycidac-C, Necitumumab, neratinib, Nilotinib, niraparib, Nivolumab, ofatumumab, obinutuzumab, olaparib, Olmesartan, Olmesartan/ hydrochlorothiazide, Omalizumab, Omega-3 fatty acid ethyl esters, Oncorine, Oseltamivir, Osimertinib, Oxycodone, palbociclib, Palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, PD-1 antibody, PD-L1 antibody, Pemetrexed, pertuzumab, Pneumococcal conjugate vaccine, pomalidomide, Pregabalin, ProscaVax, Propranolol, Quetiapine, Rabeprazole, radium 223 chloride, Raloxifene, Raltegravir, ramucirumab, Ranibizumab, regorafenib, ribociclib, Rituximab, Rivaroxaban, romidepsin, Rosuvastatin, ruxolitinib phosphate, Salbutamol, savolitinib, semaglutide, Sevelamer, Sildenafil, siltuximab, Sipuleucel-T, Sitagliptin, Sitagliptin/metformin, Solifenacin, solanezumab, Sonidegib, Sorafenib, Sunitinib, tacrolimus, tacrimus, Tadalafil, tamoxifen, Tafinlar, Talimogene laherparepvec, talazoparib, Telaprevir, talazoparib, Temozolomide, temsirolimus, Tenofovir/ emtricitabine, tenofovir disoproxil fumarate, Testosterone gel, Thalidomide, TICE BCG, Tiotropium bromide, Tisagenlecleucel, toremifene, trametinib, Trastuzumab, Trabectedin (ecteinascidin 743), trametinib, tremelimumab, Trifluridine/tipiracil, Tretinoin, Uro-BCG, Ustekinumab, Valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, ziv-aflibercept, Zostavax, and their analogs, derivatives, pharmaceutically acceptable salts, carriers, diluents, or excipients thereof, or a combination above thereof.

23. The compound according to Claim **1**, wherein the cell-binding agent/ molecule is selected from an antibody fragment that binds to a target cell.

24. The compound according to Claim **1**, wherein the G_1 and G_2 of the Formula (I-q1) are independently selected from CH_2.